Spero Therapeutics Inc. (NASDAQ:SPRO) traded with an addition of $1.87 to $2.69 on Thursday, an upside of 227.22 percent. An average of 30,166,748 shares of common stock have been traded in the last five days. There was a gain of $1.7701 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 15,399,572 shares traded, while the 50-day average volume stands at 6,290,059.
SPRO stock has decreased by -14.41% in the last month. The company shares reached their 1-month lowest point of $0.7120 on 09/02/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $0.68 and a high of $19.87 in 52 weeks. It has reached a new high 1 time so far this year and lost -94.87% or -$13.2699 in price. In spite of this, the price is down -86.47% from the 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now.
24 days have passed since Spero Therapeutics Inc. (SPRO) last reported insider trading activity. Shukla Sath, who is Chief Financial Officer, most recently acquired $6,017 shares at $0.89 per share on Aug 29. In this transaction, the insider spent $5,378. CEO and President, Mahadevia Ankit, disposed of 8,000 shares at a price of $14.58 on Dec 27. The insider now owns more than $116,666 worth of shares.
Spero Therapeutics Inc. (SPRO) stock’s beta is 1.83. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.14, the price-to-book (PB) ratio at 0.75.
The quick ratio of Spero Therapeutics Inc. for the three months ended June 29 was 3.70, and the current ratio was 3.70, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $106.23 million compared to revenue of $18.26 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Spero Therapeutics Inc.’s return on assets was -86.30%.
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$28.68 million in the quarter, while revenues of -$32.83 million were grew 35.25%. The analyst consensus anticipated Spero Therapeutics Inc.’s latest quarter earnings to come in at -$0.93 per share, but it turned out to be -$0.87, a 6.50% surprise. For the quarter, EBITDA amounted to -$25.79 million. Shareholders own equity worth $35.07 million.
From a technical analysis perspective, let’s take a brief look at Spero Therapeutics Inc. (SPRO) price momentum. RSI 9-day as of the close on 21 September was 85.48%, suggesting the stock is Overbought, with historical volatility in this time frame at 619.05%.
As of today, SPRO’s price is $1.2425 +182.48% or $1.7701 from its 5-day moving average. SPRO is currently trading +193.00% higher than its 20-day SMA and -43.62% lower than its 100-day SMA. However, the stock’s current price level is +255.86% above the SMA50 and -79.84% below the SMA200.
The stochastic %K and %D were 35.20% and 20.63%, respectively, and the average true range (ATR) was 0.3843. With the 14-day stochastic at 82.18% and the average true range at 0.2984, the RSI (14) stands at 80.93%. The stock has reached 0.3445 on the 9-day MACD Oscillator while the 14-day reading was at 0.3484.
Oppenheimer downgraded Spero Therapeutics Inc. (NASDAQ: SPRO) to a a Perform rating in its most recent analyst report. Previously, the stock was rated as an Outperform. The consensus rating for Spero Therapeutics Inc. (SPRO) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell SPRO, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 2 others rate it as a “buy”.
What is SPRO’s price target for the next 12 months?
Analysts predict a range of price targets between $2.00 and $7.00, with a median target of $5.00. Taking a look at these predictions, the average price target given by analysts for Spero Therapeutics Inc. (SPRO) stock is $4.67.